Quick heads up for those interested the following is an extract from an interesting company that listed Friday.

Disruptive technology Artrya has positioned Salix to disrupt the global market for CCTA scans and ICA procedures.

An estimated 20 million cardiac CT scans are expected to be performed in both North America and Europe alone by 2025.

By addressing current limitations in diagnostic reporting for CAD, Salix has a valuable first-mover advantage that will aid market adoption

Patients have better outcomes because Salix detects an important cause of heart attack:

Vulnerable Plaque. Diagnosis is faster, costs are lower, and there is less risk of complications by avoiding unnecessary ICA procedures.

Healthcare providers benefit because Salix integrates with existing systems, optimises practice workflows and requires no upfront capital expenditure. Diagnostic imaging practices and specialist cardiology teams can use Salix to grow their revenue by treating more patients.

Health systems benefit because Salix uses AI to provide faster reporting of CAD with less human intervention.

Salix’s personalised 3D model and automatically generated report are delivered within minutes.

By reducing treatment costs per patient, Salix aids public health systems and health insurers.

Poised for commercialisation In November 2020, SCA was included in the Australian Register of Therapeutic Goods (ARTG) as a Class 1 medical device under ID 347719. Artrya has commenced commercial pilots of SCA with Australian customers and is pursuing expansion opportunities in the United States (US), Canada and the UK.

Artrya expects first revenue from its SCA product in 2022. Artrya has a SaaS business model.

This model will help Artrya penetrate the global CCTA and ICA markets because healthcare providers pay no upfront costs to use Salix.

Typically, SaaS models have “pay-as-you-go” or subscription pricing. Artrya believes the SaaS model could deliver annuity revenue and profitable margins for the Company.